Introduction
============

Intervertebral disk degeneration (IVDD) that has unclear specific pathogenesis is mainly manifested as lower back pain and acute nerve root pain of lower extremity ([@b1-etm-0-0-8267]). Data show that the disease is extremely common worldwide. More than 80% of adults may suffer from different degrees of the degeneration ([@b2-etm-0-0-8267]), and the degree greatly increases among the middle-aged and elderly patients ([@b3-etm-0-0-8267]). As the population ages, the risk of IVDD is increasing ([@b4-etm-0-0-8267]). The disease can easily cause a series of lumbar diseases such as intervertebral disc herniation and degenerative disc diseases, even impaired walking and lower limb paralysis ([@b5-etm-0-0-8267]). According to statistics, over 40% of the lumbar diseases are mainly caused by it ([@b6-etm-0-0-8267]). Currently, the treatment of IVDD is based on conservative treatment or surgical operation, but both only relieve symptoms and cannot completely cure the disease ([@b7-etm-0-0-8267]).

Worldwide researchers are exploring new therapeutic methods for increasingly serious IVDD. With the deepening of research, increasing number of reports point out that cytobiology may be crucial to treat the disease in the future ([@b8-etm-0-0-8267],[@b9-etm-0-0-8267]). Bone morphogenetic protein (BMP) plays a pivotal role in affecting the synthesis of intervertebral disc extracellular matrix. In addition to rebuilding intervertebral disc function, its upregulation promotes the expression of type II collagen and glycoprotein in normal nucleus pulposus cells and in the extracellular matrix of degenerated nucleus pulposus ([@b10-etm-0-0-8267]). Statin simvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. Its pharmacological mechanism has been proven to upregulate BMP-2 in nucleus pulposus cells through the mevalonic acid pathway ([@b11-etm-0-0-8267]), but its clinical application is limited due to its water insolubility ([@b12-etm-0-0-8267]). As a drug sustained-release system commonly used in clinical practice, polylactic-co-glycolic acid (PLGA) can specifically administer drugs, improve drug stability, and control drug release, so it has been applied in the treatment of many diseases ([@b13-etm-0-0-8267],[@b14-etm-0-0-8267]). It is speculated that simvastatin-loaded PLGA sustained release microspheres can cure IVDD, which remains uncertain due to lack of relevant research support. Therefore, in this study, a rat model of IVDD was established, and the treatment with simvastatin-loaded PLGA microspheres was observed, and prostaglandin markers 6-keto-prostaglandin F1α (6-K-PGF1α) and hypoxia inducible factor-1α (HIF-1α) were detected to analyze the therapeutic value of simvastatin for the disease.

Materials and methods
=====================

### Animal data

Eighty 3-month-old Srague-Dawley (SD) female healthy rats, weighting 210±20 g, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., with a certificate number of SCXK (Beijing) 2016-0011. They were normally fed and housed in lighted cages (5 rats each), with the temperature of 29±2°C and the humidity of 40--50%.

Methods
-------

### Preparation of simvastatin-loaded PLGA

PLGA and simvastatin were dissolved in methylene chloride at 10:3.3, shaken and well mixed, and then added with distilled water (200 µl) for ultrasonic mixing. Next, the mixture was slowly added with 5% polyvinyl alcohol aqueous solution (100 ml) for ultrasonic mixing. Then, the mixture was added with 0.3% polyvinyl alcohol aqueous solution (50 ml), stirred, well mixed, and then allowed to stand at room temperature for 12 h. After the organic solution was removed, the mixture was frozen and dried for 48 h.

### Detection of encapsulation efficiency and drug loading of microspheres

Microspheres (5 mg) were selected and prepared into an ethanol solution (100 ml), to measure the optical density (238 nm) of the solution with ethanol as a blank control. The content of simvastatin in the microspheres was calculated according to the standard curve. Encapsulation efficiency = the total amount of simvastatin/the total amount of microspheres ×100%. Drug loading = actual drug loading/theoretical drug loading ×100%. The release curve of simvastatin was plotted according to the cumulative release.

### Modeling method

All rats were divided into four groups (n=20 each) based on random number table. Rats in the model and treatment groups were modeled for IVDD, with the method described by Chen *et al* ([@b15-etm-0-0-8267]). After the rats were intraperitoneally injected with 2% pentobarbital sodium (40 mg/kg) for anesthesia, the morphology was observed. They were determined to enter deep anesthesia if they had disappearing responses to skin pain, relaxing muscles, and disappearing responses to eye and face irritation, as well as smooth breathing. Next, the rat chest was incised to expose the lower segment of the thoracic vertebra, and the upper segment of the lumbar vertebra and the sacrum. All lumbar spinous processes, supraspinous ligaments, lumbar segment of interspinous ligaments, and posterior outer 1/2 of lumbar facet joints on both sides were removed. Subsequently, deep fascia and skin were sutured, while erector spinae muscles were not sutured, and then bilateral ovaries were removed via ventral approach. X-ray fluoroscopy was conducted to determine whether the modeling was successful. Rats in the sham operation group were anesthetized. After that, their chest was incised to expose the lower segment of the thoracic vertebra, and the upper segment of the lumbar vertebra and the sacrum. Finally, the incision was sutured. Rats in the control group were not treated. Rats in the treatment group were treated with simvastatin-loaded PLGA microspheres, and injected with normal saline (2 µl) at 5 mg/ml. Rats in the model group were injected with the same dose of normal saline.

### Outcome measures

After modeling, 5 rats in each group were sacrificed by cervical dislocation under anesthesia before simvastatin injection (T0), at 2 weeks (T1) and 4 weeks (T2) after simvastatin injection, respectively. Enzyme-linked immunosorbent assay (ELISA) was used to detect the concentrations of 6-K-PGF1α (the kit was purchased from Shanghai Hengfei Biotechnology Co., Ltd.; CSB-E14411r-1) and HIF-1α (the kit was purchased from Shanghai Qiaoyu Industrial Co., Ltd.; QY-Q11659) in the peripheral blood of rats. The lumbar vertebrae L~5-6~ of the rats were obtained, and the bone mineral density (BMD) of L~5~ and L~6~ was detected by X-ray. After the injection, CT was carried out to scan the vertebral body of the rats and reconstruct the scanned area in three dimensions. The trabecular thickness, number, and separation of the vertebral body were detected. Changes in the sagittal T2-weighted signal were detected by MRI to detect the intervertebral disc nucleus pulposus of the rats.

### Evaluation program of humane endpoint

Weight loss: The rats lost 15--20% of the original body weight within 2 days, or they had no sustained weight gain in growth period, or they had cachexia and sustained muscle consumption without weight monitoring. Weakness: The rats were unable to feed and drink on their own, and they were unable to stand for 24 h or they could stand with extreme efforts. The recovery period after anesthesia was excluded, and then whether they were weak due to diseases, experiments, or other factors was evaluated. Organ infection: The rats had abnormal physical indices and blood test values, but no good response to drug treatment; additionally, the disease progressed to a systemic disease. Respiratory system: The rats had severe respiratory tract infection, dyspnea, or cyanosis. Circulatory system: The rats had severe anemia, uncontrollable hemorrhage (PVC \<15%), or jaundice. Nervous system: The rats had abnormal central nervous system reactions (convulsion, trembling, paralysis, and torticollis) or uncontrollable pain. Others: The rats had persistent self-mutilation behavior, non-healing wounds, diseases that seriously affected eating and drinking water, advanced infectious diseases, persistent hypothermia, significant functional damage to organs and facial features, or behaviors and physiological phenomena when they suffered from distress and pain. The study was approved by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong University.

### Death determination

The rats were laid on one side and they were determined to be dead if they could not turn over to a normal posture within 30 sec.

### Statistical analysis

In this study, SPSS 24.0 (Shanghai Yuchuang Network Technology Co., Ltd.) was used to statistically analyze the results. GraphPad 8 (Softhead Inc.) was used to plot figures. Enumeration data were expressed by rate, and Chi-square test was used for comparison between groups. Measurement data were expressed as mean ± standard deviation, and t-test was used for comparison between groups. Repeated measures analysis of variance and Bonferroni post hoc test were used for comparison between multiple time-points. P\<0.050 indicated a statistically significant difference.

Results
=======

### Simvastatin-loaded PLGA sustained release microspheres

The drug loading of the microspheres was 22.85±1.85%, and the encapsulation efficiency was 91.12±2.78%, and the cumulative release was \>80%, which indicated successful preparation ([Fig. 1](#f1-etm-0-0-8267){ref-type="fig"}).

### Modeling results

Of the 40 rats modeled, 20 in the treatment group and 19 in the model group were successfully modeled, with a success rate of 97.5%.

### Detection results of BMD

At T0, there was no significant difference in BMD between the treatment and model groups (P\>0.050), and between the sham operation and control groups (P\>0.050). BMD in the model and treatment groups was lower than that in the sham operation and control groups (P\<0.050). At T1, there was no significant difference between the sham operation and control groups (P\>0.050). BMD in the two groups was higher than that in the model and treatment groups, while BMD in the treatment group was higher than that in the model group (P\<0.050). At T2, there was no significant difference between the sham operation, control, and treatment groups (P\>0.050), and BMD in the three groups was higher than that in the model group (P\<0.050). There was no difference in BMD at T0, T1 and T2 between the sham operation, control, and model groups (P\>0.050). BMD in the treatment group was the lowest at T0 and the highest at T2 (P\<0.050) ([Fig. 2](#f2-etm-0-0-8267){ref-type="fig"}).

### 6-K-PGF1α and HIF-1α

At T0, there were no differences in 6-K-PGF1α and HIF-1α between the control and sham operation groups (P\>0.050), but there were differences between the model and treatment groups (P\>0.050). The two indices in the control and sham operation groups were higher than those in the model and treatment groups (P\<0.050). At T1 and T2, there were no differences between the control and sham operation groups (P\>0.050). The two indices in the two groups were higher than those in the treatment and model groups (P\<0.050), while those in the treatment group were higher than those in the model group (P\<0.050). There were no differences in the indices at T0, T1 and T2 between the control and sham operation groups (P\<0.050). The indices in the model group were the highest at T0 and the lowest at T2 (P\<0.050). The indices in the treatment group were the lowest at T0 and the highest at T2 (P\<0.050) ([Fig. 3](#f3-etm-0-0-8267){ref-type="fig"}).

### CT results

There was no difference in the trabecular thickness between the four groups (P\>0.050), and in the trabecular number and separation between the control and sham operation groups (P\>0.050). The trabecular number in the control and sham operation groups was higher than that in the treatment and model groups, and that in the model group was the lowest (P\<0.050). The trabecular separation in the two groups was lower than that in the treatment and model groups, and that in the model group was the highest (P\<0.050) ([Table I](#tI-etm-0-0-8267){ref-type="table"}).

### MRI results

After 8-week injection, there was no difference in the sagittal T2-weighted MRI signal of the intervertebral disc nucleus pulposus between the control and sham operation groups (P\>0.050). The signal in the two groups was higher than that in the model and treatment groups (P\<0.050), and that in the model group was the lowest ([Fig. 4](#f4-etm-0-0-8267){ref-type="fig"}).

Discussion
==========

IVDD is a very common chronic disease around the world with a high incidence and great harm, so it has long been a major research project in clinical practice ([@b16-etm-0-0-8267]). The effect of simvastatin on IVDD has been unanimously agreed, it improves bone quality by promoting the aggregation of type II collagen. However, it has not yet been widely used in clinical practice due to its extremely high limitation in human body ([@b17-etm-0-0-8267]). In this study, the effects of simvastatin-loaded PLGA microspheres on treating rats with IVDD were observed, to analyze the effective scheme of simvastatin in the treatment. In addition, 6-K-PGF1α and HIF-1α in the rats were detected to preliminarily analyze the influencing mechanism of simvastatin, which is of great significance for the clinical treatment of the disease in the future.

In this study, BMD in the treatment group was significantly higher than that in the model group after treatment, but partial BMD was not significantly different from that in the control group at T2. This confirms the important role of simvastatin in the bone tissue and the feasibility of treating IVDD with simvastatin-loaded PLGA sustained release microspheres, which was also proved by comparing the trabecular number, the trabecular separation, and the sagittal T2-weighted MRI signal between the four groups. Organic polymer material PLGA has good biodegradability, compatibility, non-irritant, and non-immunogenicity, so it has a great application prospect in clinical practice ([@b18-etm-0-0-8267]). PLGA was chosen as the sustained-release material of simvastatin, because its excellent drug loading, encapsulation efficiency, and release ensure its stable concentration for homeostasis during the action of simvastatin on IVDD. Many studies have confirmed that simvastatin mainly affects the intervertebral disc by upregulating BMP-2 ([@b19-etm-0-0-8267],[@b20-etm-0-0-8267]), which was therefore not repeated here. According to the detection, 6-K-PGF1α and HIF-1α at T0 in the treatment and model groups were lower than those in the control and sham operation groups, while the two indices in the treatment group significantly increased at T1 and T2, and were higher than those in the control and sham operation groups at T2. These findings suggest that simvastatin has a significant effect on 6-K-PGF1α and HIF-1α. Prostaglandin I~2~ (PGI~2~), a substance reflecting bioactivity and produced by arachidonic acid metabolism, dilates blood vessels and controls platelet aggregation ([@b21-etm-0-0-8267]). In human body, it is quickly hydrolyzed into inactive 6-K-PGF1α and maintains blood circulation ([@b22-etm-0-0-8267]). Fan *et al* ([@b23-etm-0-0-8267]) investigated the role of 6-K-PGF1α in hyperlipidemia and found that it is important for the formation of thrombosis. Although the pathogenesis of IVDD is not yet clear, previous studies have shown that the number of vascular buds in cartilage endplate decreases during pathogenesis, so hemodynamic abnormality may be a pathogenic factor for the disease ([@b24-etm-0-0-8267]). The significant effect of 6-K-PGF1α on hemodynamics may also be a mechanism of simvastatin in the treatment of IVDD. It is speculated that simvastatin may play an antithrombotic role by increasing the content of 6-K-PGF1α, so as to enhance the hemodynamics of patient tissues, and then protect and improve the integrity of bone tissues. 6-K-PGF1α usually functions in human body through coordinating with thromboxane A~2~ (TXA~2~). In this study, TXA~2~ in each group was not detected, but it is a research emphasis in the future. As an important cytokine that makes tissues and cells adapt rapidly to low oxygen environment, HIF-1α promotes the generation of vascular endothelial growth factor (VEGF) and glucose receptor, and regulates cell apoptosis and differentiation ([@b25-etm-0-0-8267]). Lumbar intervertebral disc cells have been in a low oxygen microenvironment for a long time due to the aging of the body. At this time, HIF-1α is activated, which accelerates the synthesis of VEGF and protein ([@b26-etm-0-0-8267]). The increase in HIF-1α after simvastatin injection is possibly because the upregulation of VEGF expression promotes cardiovascular formation in the intervertebral disc tissue, thus delaying the progression of IVDD. Additionally, studies have confirmed the close correlations of 6-K-PGF1α and HIF-1α with BMP-2 ([@b27-etm-0-0-8267],[@b28-etm-0-0-8267]). However, it is also possible that simvastatin regulates 6-K-PGF1α and HIF-1α through BMP-2 and then affects IVDD, which needs further confirmation.

This study has deficiencies due to the limited experimental conditions. For example, because of the differences between animal models and human beings, the concentration of simvastatin should be further confirmed, and the drug resistance of humans should be considered.

In conclusion, simvastatin-loaded PLGA sustained release microspheres can improve the BMD of the vertebral body and increase the contents of 6-K-PGF1α and HIF-1α in the treatment of rats with IVDD, so they are important for the clinical treatment of the disease.
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![Detection results of BMD. (A) Comparison of the BMD of L~5~ vertebral body between the four groups. (B) Comparison of the BMD of L~6~ vertebral body between the four groups. \*P\<0.050 when compared with BMD in the control group at the same time-point; ^\#^P\<0.050 when compared with BMD in the sham operation group at the same time-point; ^&^P\<0.050 when compared with BMD in the model group at the same time-point; ^@^P\<0.050 when compared with BMD at T0 in the same group; ^\$^P\<0.050 when compared with BMD at T1 in the same group.](etm-19-01-0579-g01){#f2-etm-0-0-8267}

![Detection results of 6-K-PGF1α and HIF-1α. (A) Comparison of 6-K-PGF1α between the four groups. (B) Comparison of HIF-1α between the four groups. \*P\<0.050 when compared with that in the control group at the same time-point; ^\#^P\<0.050 when compared with that in the sham operation group at the same time-point; ^&^P\<0.050 when compared with that in the model group at the same time-point; ^\$^P\<0.050 when compared with that at T0 in the same group; ^@^P\<0.050 when compared with that at T1 in the same group.](etm-19-01-0579-g02){#f3-etm-0-0-8267}

![Comparison of sagittal T2-weighted MRI signal of intervertebral disc nucleus pulposus. \*P\<0.050 when compared with that in the control group; ^\#^P\<0.050 when compared with that in the sham operation group; ^@^P\<0.050 when compared with that in the model group.](etm-19-01-0579-g03){#f4-etm-0-0-8267}

###### 

Comparison of CT results.

                               Control        Sham operation group   Model group                                                                                               Treatment group                                                                                            F-value   P-value
  ---------------------------- -------------- ---------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------- ---------
  Trabecular thickness (µm)    105.52±4.28    101.52±3.15            103.62±3.42                                                                                               103.57±4.16                                                                                                0.933     0.448
  Trabecular number (mm)       2.34±0.42      2.28±0.39              1.42±0.24^[a](#tfn1-etm-0-0-8267){ref-type="table-fn"},[b](#tfn2-etm-0-0-8267){ref-type="table-fn"}^      1.83±0.25^[a](#tfn1-etm-0-0-8267){ref-type="table-fn"}--[c](#tfn3-etm-0-0-8267){ref-type="table-fn"}^      8.249     0.002
  Trabecular separation (µm)   250.62±28.63   262.61±30.57           368.45±32.65^[a](#tfn1-etm-0-0-8267){ref-type="table-fn"},[b](#tfn2-etm-0-0-8267){ref-type="table-fn"}^   316.74±25.61^[a](#tfn1-etm-0-0-8267){ref-type="table-fn"}--[c](#tfn3-etm-0-0-8267){ref-type="table-fn"}^   16.880    \<0.001

P\<0.050 when compared with that in the control group

P\<0.050 when compared with that in the sham operation group

P\<0.050 when compared with that in the model group.
